CannTrust Partnering with Australian Hospital for Trial Testing Cannabidiol Capsules for ALS

CannTrust is getting ready to launch a clinical trial to assess the effectiveness of its cannabidiol (CBD) oil capsules on slowing the progression of amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs).

This new study is the result of a collaboration between Canada-based CannTrust and Gold Coast University Hospital, one of the leading tertiary referral institutions in Australia for ALS management.

“This study will help advance our understanding of the potential effects of CannTrust’s standardized CBD oil capsules on ALS/MND, both as a disease modifying agent and as a symptomatic treatment and will become the basis for conducting future cannabinoid and ALS clinical trials,” Arman Sabet, MD, a neurologist at Gold Coast University Hospital and the lead researcher of the study, said in a press release.

The randomized, double-blind, placebo-controlled study will assign participants to receive either CannTrust’s standardized CBD

... read more at: https://alsnewstoday.com/2018/07/17/canntrust-launching-trial-testing-cannabidiol-capsules-als-treatment/